Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast
Authors:
- Lucinda OrsiniLOLucinda Orsini
- Sasigaant Limpa-AmaraSLSasigaant Limpa-Amara
- William H. CrownWCWilliam H. Crown
- Richard H. StanfordRSRichard H. Stanford
- Khalid KamalKKKhalid Kamal
- 1 May 2004
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 92 (5) , 523-529
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Low-Dose Inhaled Corticosteroid Therapy and Risk of Emergency Department Visits for AsthmaArchives of internal medicine (1960), 2002
- The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonistJournal of Allergy and Clinical Immunology, 2002
- The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexesJournal of Health Economics, 2002
- Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukastRespiratory Medicine, 2001
- One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthmaJournal of Allergy and Clinical Immunology, 2001
- Inhaled Fluticasone PropionatePharmacoEconomics, 2000
- Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapyAnnals of Allergy, Asthma & Immunology, 2000
- Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working AdultsJAMA, 2000
- Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups.American Journal of Public Health, 1997